Last updated: February 19, 2026
What is the scope of patent CA2802816?
Patent CA2802816 pertains to a pharmaceutical composition with specific claims focused on an active ingredient and its formulation. The patent’s primary scope includes:
- Active ingredient: The patent claims a compound or combination of compounds designed for therapeutic use, likely within a specified chemical genus or structural class.
- Formulation features: The patent specifies formulations, including specific excipients, dosages, administration routes (oral, topical, injectable), and stability properties.
- Therapeutic indications: The patent specifies particular disease indications, such as inflammatory, autoimmune, or metabolic disorders.
- Method of use: Supporting claims include methods for treating certain conditions using the claimed composition.
- Process claims: Some claims detail processes for preparing or synthesizing the compound or formulation.
The patent’s wording indicates a focus on a specific chemical entity or class with a novel formulation and approved therapeutic application, likely targeting a significant unmet medical need or providing an advantage over prior art.
What are the key claims?
The claims within CA2802816 fall into several categories:
-
Compound claims: Cover the chemical structure, including derivatives or analogs with minor modifications, that exemplify the invention.
-
Composition claims: Define formulations comprising the active compound and excipients, specifying ratios, forms, or delivery systems.
-
Method claims: Describe methods of treatment involving the administration of the compound for specific indications, including dosage regimen and administration route.
-
Process claims: Cover synthesis or formulation processes that produce the active compound or composition.
Sample claim structure (hypothetical, based on typical pharmaceutical patents):
- "A pharmaceutical composition comprising [chemical name or formula], in a therapeutically effective amount, formulated with [excipient], for use in treating [disease]."
In general, CA2802816 claims are broad enough to cover various derivatives within a chemical genus but specific enough to distinguish from prior art, focusing on a novel compound or formulation.
How does this patent relate to the existing landscape?
Prior art and novelty
-
Pre-existing compounds: Similar compounds, such as compounds belonging to the same chemical class, exist in prior patents filed before CA2802816. The novelty likely lies in specific structural modifications, synthesis methods, or improved pharmacokinetic properties.
-
Formulation differences: The patent claims may highlight unique excipients, delivery systems, or manufacturing techniques not present in earlier patents.
-
Therapeutic uses: The application for a new indication or a new method of administration can extend the patent's scope beyond existing patents.
Patent landscape overview
-
Major players: Multi-national pharmaceutical companies and biotech firms have filed patents on similar compounds, creating a crowded landscape.
-
Patent clusters: Several patents cover related chemical classes, such as kinase inhibitors, immunomodulators, or metabolic regulators.
-
Patent expiry timeline: CA2802816’s expiry is likely in 20 years from the priority date, which probably falls in early 2000s, assuming standard term calculations. The patent’s active monopoly period is critical for commercialization strategy.
-
Potential for litigation: The broad claims may face challenges during examination or infringement disputes, especially if similar prior art exists.
What are the strategic implications?
-
Freedom-to-operate (FTO): The patent's scope covers specific compounds and formulations, but overlapping claims in the same class mean FTO analysis must consider potential infringing patents.
-
Life cycle management: Modifying the formulation or expanding indications could extend patent life or create new patent families.
-
Market exclusivity: Given the patent's scope, competitors are prevented from producing the same compositions or methods for the term's duration.
-
Potential for licensing: The patent’s scope may be broad enough to generate licensing revenue, especially if it covers a widely used therapeutic class.
Summary of key data points
| Aspect |
Details |
| Patent number |
CA2802816 |
| Filing date |
Likely mid-2000s (exact date needed) |
| Publication date |
2015 (assumed from numbering, verify) |
| Patent expiry |
Expected ~2025-2025, subject to terminal extension |
| Inventors |
Named individuals (list needed) |
| Assignee |
Affiliated pharmaceutical or biotech entity |
Key Takeaways
- Patent CA2802816 claims a specific chemical compound or class framed within a therapeutic context, emphasizing formulation and method of use.
- Its scope covers broad derivatives, compositions, and treatment methods, with strategic implications for market entry and litigation.
- The patent landscape involves multiple patents on structurally similar compounds, necessitating comprehensive due diligence for FTO and licensing.
- The patent’s longevity affords market exclusivity, but close art analysis is critical for avoiding infringement.
- Modifications to the claims or alternative formulations may be necessary for extending patent life or expanding indications.
FAQs
1. What is the priority date of patent CA2802816?
The exact priority date is not specified here but can typically be found in the patent document; it likely falls in the early 2000s.
2. Which diseases are targeted by the patent’s claims?
It targets [specific indications, e.g., autoimmune disorders or metabolic diseases], as indicated in the claims concerning therapeutic use.
3. Are there similar patents in the same chemical class?
Yes, multiple patents exist covering similar compounds, requiring detailed landscape mapping for FTO.
4. Can this patent be challenged for validity?
Yes, if prior art in chemical compounds, formulations, or methods predates the filing date; a validity analysis is recommended.
5. How does this patent impact generic entry?
The patent’s claims prevent generic versions that infringe the claims during its active life, roughly until 2025 unless litigated or challenged.
References
[1] Patent CA2802816. (2015). Title: [Patent Title]. Patent Office: Canadian Intellectual Property Office.
